The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Cell Secretome: Basic Insights and Therapeutic Opportunities for CNS Disorders
Open accessAbstract
Transplantation of stem cells, in particular mesenchymal stem cells (MSCs), stands as a promising therapy for trauma, stroke or neurodegenerative conditions such as spinal cord or traumatic brain injuries (SCI or TBI), ischemic stroke (IS), or Parkinson’s disease (PD). Over the last few years, cell transplantation-based approaches have started to focus on the use of cell byproducts, with a strong emphasis on cell secretome. Having this in mind, the present review discusses the current state of the art of secretome-based therapy applications in different central nervous system (CNS) pathologies. For this purpose, the following topics are discussed: (1) What are the main cell secretome sources, composition, and associated collection techniques; (2) Possible differences of the therapeutic potential of the protein and vesicular fraction of the secretome; and (3) Impact of the cell secretome on CNS-related problems such as SCI, TBI, IS, and PD. With this, we aim to clarify some of the main questions that currently exist in the field of secretome-based therapies and consequently gain new knowledge that may help in the clinical application of secretome in CNS disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Number of publications per year of cell-, secretome-, or exosome-based therapies on central nervous system (CNS) disorders (Parkinson’s disease (PD), spinal cord injury (SCI), traumatic brain injury (TBI) and ischemic stroke (IS)). An electronic research on PubMed database for literature describing cell-, secretome-, and exosome-based therapies was performed on 18 January 2019 using the following keywords: (cell OR cellular OR stem OR cells) AND (transplantation OR transplant OR “Co-Transplantation” OR Cotransplantation OR engraft OR engraftment OR graft OR grafts) AND (therapy OR therapies OR therapeutics OR therapeutic) NOT Review [Publication Type] AND (“spinal cord injury” or “brain injury” or stroke or parkinson) AND (primates OR mice OR mouse OR rat OR rats OR rodent OR “in vivo” OR “clinical Trials” OR humans) for cell-based therapies and (conditioned medium OR conditioned media OR secretory OR “trophic factors” OR Exosomes OR vesicles OR microvesicles OR vesicular OR “Extracellular vesicles” OR “nanovesicles” OR “exosomal”) AND (therapy OR therapies OR therapeutics OR therapeutic) NOT Review[Publication Type] AND (“spinal cord injury” or “brain injury” or stroke or parkinson) AND (primates OR mice OR mouse OR rat OR rats OR rodent OR “in vivo” OR “clinical Trials” OR humans) for secretome- and exosome-based therapies. The search retrieved 3676 articles for cell-based therapies and 682 articles for secretome- and exosome-based therapies. Data extraction was independently performed by two researchers.](https://figures.cochat.ai/paper-figures/a37d098deb8648058a26f97d504e4a48/cell-secretome-basic-insights-and-therapeutic-opportunities-for-cns-disorders-figure-1.jpg)
![Figure 2 Mesenchymal stem cell secretome composition and their main effects on the CNS. On their soluble fraction (red circles), MSC secretome contains cytokines, chemokines, growth factors, and glycoproteins. On their vesicular fractions (orange circles), the exosomes and microvesicles contain essentially microRNAs. Both the soluble and the vesicular fractions may act on distinct damaged cells of the nervous system, promoting their survival, angiogenesis, neurite outgrowth, and immunomodulation. This information is based on the articles [85,86].](https://figures.cochat.ai/paper-figures/6a9797bee1d545a395bd5dd96ec7519b/cell-secretome-basic-insights-and-therapeutic-opportunities-for-cns-disorders-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It involves the in vitro modulation of the secretome produced by MSC by exposing these cells to specific factors that usually mimic the tissue damage microenvironment [73], namely to hypoxia, inflammatory or disease-specific cytokines and/or pharmacological compounds, or even by using 3-dimensional (3D) cell culture systems [54], [120], [121].”
From Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? (2025) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“Multiple studies exploring strategies of modulating environmental factors with the potential to enhance the beneficial effects of secretome-contained biomolecules have been performed, namely via preconditioning [18], [54], [120].”
From Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? (2025) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Biological properties of extracellular vesicles and their physiological functions
Yáñez‐Mó, M., Siljander, P. R. ‐., Andreu, Z., Bedina Zavec, A., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27066 · Cited by 5,926 · cited 1×
“biologic content on cell cytoplasm, finally inducing angiogenesis [91,92] and neurite outgrowth [93,94] and regulating inflammatory responses [95,96].”
BackgroundMathieu, M., Martin-Jaular, L., Lavieu, G., & Théry, C. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0250-9 · Cited by 3,737 · cited 1×
“However, the vesicular fraction by itself could also constitute a powerful therapeutic approach since EVs are similarly involved in intercellular communication and may contain all the signals required for a successful contact [101].”
BackgroundEstimating the global incidence of traumatic brain injury
Dewan, M. C., Rattani, A., Gupta, S., Baticulon, R. E., Hung, Y.-C., Punchak, M., Agrawal, A., Adeleye, A. O., Shrime, M. G., Rubiano, A. M., et al. (2019) · Journal of Neurosurgery · doi:10.3171/2017.10.jns17352 · Cited by 3,291
Regeneration beyond the glial scar
Silver, J., & Miller, J. H. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1326 · Cited by 3,078 · cited 1×
“, cellular dysfunction or death, overactivation of immune cells, production of reactive oxygen species or proteoglycans, and glial scar formation) that exacerbate the primary insult [9,10].”
BackgroundMesenchymal stem cells as trophic mediators
Caplan, A. I., & Dennis, J. E. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20886 · Cited by 2,992 · cited 1×
“Indeed, factors such as GDNF, NGF, HGF, VEGF, IGF-1 and 2, chemokine (C-X-C motif) ligand (CXCL 16), IL-6 and 10, TGF β1, and MCP-1 have been related to the neuro- and immunoregulatory character of MSC secretome [63,87,99,100].”
BackgroundSecretion of angiogenic and antiapoptotic factors by human adipose stromal cells
Rehman, J., Traktuev, D., Li, J., Merfeld-Clauss, S., Temm-Grove, C. J., Bovenkerk, J. E., Pell, C. L., Johnstone, B. H., Considine, R. V., & March, K. L. (2004) · Circulation · doi:10.1161/01.cir.0000121425.42966.f1 · Cited by 2,269 · cited 1×
“Similarly to what has been reported for BM-MSCs, growth factors such as vascular endothelial growth factor (VEGF), glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), hepatocyte growth factor (HGF), fibroblast growth factor (FGF), nerve growth factor (NGF), insulin-like growth factors 1…”
BackgroundThe prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188
Exosomes as drug delivery vehicles for Parkinson’s disease therapy
Haney, M. J., Klyachko, N. L., Zhao, Y., Gupta, R., Plotnikova, E. G., He, Z., Patel, T., Piroyan, A., Sokolsky, M., Kabanov, A. V., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.033 · Cited by 2,009
Vlassov, A. V., Magdaleno, S., Setterquist, R., & Conrad, R. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.03.017 · Cited by 1,930 · cited 1×
“, messenger RNAs and microRNAs) and small proteins are secreted through membranal fusion to the extracellular space [89,90].”
Background
Research works printed but not linked: 1
- Chang, 2013, Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury, Clin. Sci., 124, 165, 10.1042/cs20120226 · DOI · Paper page
Cited by
Mesenchymal stem cell secretome for regenerative medicine: Where do we stand?
Trigo, C. M., Rodrigues, J. S., Camões, S. P., Solá, S., & Miranda, J. P. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.05.004 · Cited by 252
“…have an important role in mediating the regenerative and immunomodulatory properties of MSCs [51,52], a completely consensus is not established [53,54], with some data showing that the total MSC-secretome and MSC-EV-free fraction had better immunomodulatory effects when compared with MSC-EVs…”
InfluentialDental Pulp Stem Cell-Derived Secretome and Its Regenerative Potential
Bar, J. K., Lis-Nawara, A., & Grelewski, P. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112018 · Cited by 142
Pathophysiology and Therapeutic Approaches for Spinal Cord Injury
Lima, R., Monteiro, A., Salgado, A. J., Monteiro, S., & Silva, N. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213833 · Cited by 141
Self-citationZhou, X. J., Chu, X., Yuan, H., Qiu, J., Zhao, C., Xin, D., Li, T., Ma, W., Wang, H., Wang, Z., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108818 · Cited by 115
Mesenchymal Stem Cell-Based Therapy for Stroke: Current Understanding and Challenges
Li, W., Shi, L., Hu, B., Hong, Y., Zhang, H., Li, X., & Zhang, Y. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.628940 · Cited by 115
“They can be isolated from almost all tissues in mammals including bone marrow (BM), adipose tissue or other tissues (Pinho et al., 2020) and are easy to culture and effectively expand.”
Background
Metadata
- Authors
- Pinho, A. G., Cibrão, J. R., Silva, N. A., Monteiro, S., & Salgado, A. J.
- Affiliations
- University of Minho (PT)
- Corresponding author
- Salgado, António J.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2020-02-20
- Volume
- 13
- Issue
- 2
- Pages
- 31
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC7169381
- OpenAlex
- W3007972554
- Cited by
- 94
- References
- 155
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 18 · 2023: 15 · 2022: 17 · 2021: 12 · 2020: 5
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by-nc-nd)
- Funders
- FUNDAÇÃO PARA A CIÊNCIA E TECNOLOGIA, SANTA CASA NEUROSCIENCE AWARDS, NORTE 2020, FEDER, COMPETE (MC-04/17; CEECIND/04794/2017; CEECIND/01902/2017; POCI-01-0145-FEDER-007038; TUBITAK/0007/2014; POCI-01-0145-FEDER-029206, POCI-01-0145-FEDER-029751; NORTE-01-0145-FEDER-029968; NORTE-01-0145-FEDER-000013 and NORTE-01-0145-FEDER-000023)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Clinical Neurology › Spinal Cord Injury Research
- Keywords
- secretome, mesenchymal stem cells, cell transplantation, extracellular vesicles, spinal cord injury, traumatic brain injury, ischemic stroke, Parkinson's disease, central nervous system disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cell Secretome: Basic Insights and Therapeutic Opportunities for CNS Disorders. https://app.cochat.ai/papers/10.3390/ph13020031
- The paper
- Pinho, A. G., Cibrão, J. R., Silva, N. A., Monteiro, S., & Salgado, A. J. (2020). Cell Secretome: Basic Insights and Therapeutic Opportunities for CNS Disorders. Pharmaceuticals. https://doi.org/10.3390/ph13020031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.